These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25424141)

  • 1. [Cost-effectiveness and budget impact of ivabradine in heart failure therapy].
    Polistena B; Maggioni AP; Oliva F; Spandonaro F
    G Ital Cardiol (Rome); 2014 Nov; 15(11):626-33. PubMed ID: 25424141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
    Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
    Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
    Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
    BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
    Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27153871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN TREATMENT OF PATIENTS WITH HEART FAILURE IN IRAN.
    Taheri S; Heidari E; Aivazi MA; Shams-Beyranvand M; Varmaghani M
    Int J Technol Assess Health Care; 2018; 34(6):576-583. PubMed ID: 30560749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
    Adena MA; Hamann G; Sindone AP
    Heart Lung Circ; 2019 Mar; 28(3):414-422. PubMed ID: 29449079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands.
    Mokri H; Clephas PRD; de Boer RA; van Baal P; Brugts JJ; Rutten-van Mölken MPMH
    Eur J Heart Fail; 2024 May; 26(5):1189-1198. PubMed ID: 38560762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting.
    Cowie MR; Cure S; Bianic F; McGuire A; Goodall G; Tavazzi L
    Eur J Heart Fail; 2011 Jun; 13(6):681-9. PubMed ID: 21474462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
    Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D
    J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.
    Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
    Adv Ther; 2017 Mar; 34(3):753-764. PubMed ID: 28205056
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.